NSIM
ALNY icon

North Star Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

North Star Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01K Buy
10
+3
+43% +$905 ﹤0.01% 1356
2026
Q1 		$2.32K Buy
+7
New +$2.38K ﹤0.01% 1386

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

North Star Investment Management's ALNY Position: Q2 2026 in Review

North Star Investment Management increased its Alnylam Pharmaceuticals (ALNY) stake by 43% in Q2 2026, buying an estimated $905 and bringing the position to 10 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

North Star Investment Management first reported a position in ALNY in Q1 2026 and has held it in 2 quarters since. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • North Star Investment Management held 10 shares of Alnylam Pharmaceuticals worth $3.01K as of Q2 2026.
  • North Star Investment Management bought 3 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $905.
  • Alnylam Pharmaceuticals made up ﹤0.01% of North Star Investment Management's portfolio in Q2 2026, its #1356 holding.
  • North Star Investment Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on North Star Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.